GlaxoSmithKline Pharmaceuticals Limited (GLAXO) AI Stock Analysis

• Market Cap: ₹438.49B
• Dividend Yield: 2.09%
• Average Volume (3M): 1.83K
• Price to Earnings (P/E): 45.9
• Beta (1Y): 0.72
• Revenue Growth: 4.17%
• EPS Growth: 41.51%
• Country: IN
• Employees: 3,211
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 15.00
• Shares Outstanding: 169,406,040
• 10 Day Avg. Volume: 1,472
• 30 Day Avg. Volume: 1,831
• PEG Ratio: 0.89
• Price to Book (P/B): 24.29
• Price to Sales (P/S): 12.64
• P/FCF Ratio: 37.41
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: ₹2,860.00 ▲(10.78% Upside)

GlaxoSmithKline Pharmaceuticals Limited's strong financial performance is the most significant factor, showcasing robust profitability and efficient cash flow management. However, the technical analysis indicates bearish momentum, and the high P/E ratio suggests potential overvaluation. The absence of earnings call data and corporate events limits further insights.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Cash Flow Management

Strong cash flow growth enhances financial flexibility, enabling the company to invest in growth opportunities and manage debt effectively.

Profitability

High profitability margins reflect efficient cost management and pricing power, contributing to sustainable earnings over time.

Negative Factors

Bearish Technical Indicators

Persistent bearish technical indicators may signal market skepticism or underlying business challenges, potentially affecting investor confidence.

High Valuation Concerns

A high valuation compared to peers can limit upside potential and may indicate overvaluation, impacting long-term investment attractiveness.

Lack of Recent Corporate Events

The absence of recent corporate events may suggest a lack of strategic initiatives or innovations, potentially affecting future growth prospects.

GlaxoSmithKline Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) is a global healthcare company focused on the research, development, and manufacturing of pharmaceuticals, vaccines, and consumer healthcare products. With a diverse portfolio that includes treatments for respiratory, HIV, oncology, and immunology conditions, GLAXO aims to improve health and well-being across various populations. The company operates in three main sectors: Pharmaceuticals, Vaccines, and Consumer Healthcare, leveraging scientific innovation to deliver effective solutions to patients and consumers worldwide.

How the Company Makes Money

GLAXO generates revenue primarily through the sale of its pharmaceutical products, vaccines, and consumer healthcare items. The Pharmaceuticals segment contributes significantly to revenue through prescription drugs that treat various diseases and conditions. The Vaccines division profits from the distribution of immunizations globally, often supported by government contracts and public health initiatives. Additionally, the Consumer Healthcare sector provides over-the-counter products, which are sold directly to retailers and consumers. Key revenue streams include direct sales to hospitals and pharmacies, long-term agreements with healthcare providers, and collaborations with other pharmaceutical companies for joint research and product development. Strategic partnerships and licensing agreements further enhance revenue potential, allowing GLAXO to expand its market reach and innovate within the competitive healthcare landscape.

GlaxoSmithKline Pharmaceuticals Limited Financial Statement Overview

Summary

GlaxoSmithKline Pharmaceuticals Limited exhibits a strong financial profile with impressive revenue growth, robust profitability, and efficient cash flow management. The company maintains a solid balance sheet with low leverage and high liquidity, positioning it well for future opportunities and challenges in the pharmaceutical industry.

Income Statement

GlaxoSmithKline Pharmaceuticals Limited shows strong financial performance with a consistent increase in total revenue over the years. For the latest fiscal year, the company achieved a Gross Profit Margin of 62.88% and a Net Profit Margin of 24.74%, indicating healthy profitability. The Revenue Growth Rate was 8.92%, showcasing robust top-line growth. Additionally, the company reported a solid EBIT Margin of 47.45% and an EBITDA Margin of 31.40%, reflecting efficient operational management.

Balance Sheet

The balance sheet demonstrates a strong financial position with a low Debt-to-Equity Ratio of 0.005, suggesting minimal financial leverage. The Return on Equity (ROE) stands at 47.53%, indicating efficient use of equity to generate profits. The Equity Ratio of 47.50% highlights a balanced capital structure. The company maintains substantial liquidity, evidenced by significant cash reserves.

Cash Flow

The cash flow analysis reveals positive trends with a substantial Free Cash Flow Growth Rate of 129.96% in the latest fiscal year. The Operating Cash Flow to Net Income Ratio is 1.39, suggesting strong cash generation relative to net income. Additionally, the Free Cash Flow to Net Income Ratio is 1.37, reflecting robust cash flow management and the ability to support ongoing operations and investments.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	37.40B	37.49B	34.54B	32.52B	32.78B	29.26B
Gross Profit	23.33B	23.35B	20.99B	19.48B	19.00B	16.43B
EBITDA	11.82B	11.53B	8.81B	7.88B	7.43B	5.73B
Net Income	9.50B	9.28B	5.90B	6.11B	16.95B	3.58B
Balance Sheet
Total Assets	0.00	41.08B	35.57B	33.27B	46.33B	31.13B
Cash, Cash Equivalents and Short-Term Investments	24.98B	24.98B	18.57B	16.54B	29.03B	11.63B
Total Debt	0.00	99.50M	186.65M	155.40M	200.76M	346.27M
Total Liabilities	-19.51B	21.57B	17.79B	15.85B	19.70B	16.14B
Stockholders Equity	19.51B	19.51B	17.78B	17.41B	26.63B	14.78B
Cash Flow
Free Cash Flow	0.00	12.67B	5.51B	4.40B	7.76B	5.34B
Operating Cash Flow	0.00	12.90B	5.82B	4.84B	8.11B	5.78B
Investing Cash Flow	0.00	-458.10M	87.12M	8.08B	-4.06B	4.19B
Financing Cash Flow	0.00	-7.69B	-5.61B	-15.43B	-5.24B	-6.96B

GlaxoSmithKline Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2581.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GLAXO, the sentiment is Neutral. The current price of 2581.7 is above the 20-day moving average (MA) of 2539.39, below the 50-day MA of 2605.53, and below the 200-day MA of 2840.52, indicating a neutral trend. The MACD of 2.63 indicates Negative momentum. The RSI at 52.67 is Neutral, neither overbought nor oversold. The STOCH value of 67.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:GLAXO.

GlaxoSmithKline Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DRREDDY	74 Outperform	₹1.07T	18.20	―	0.62%	14.10%	9.72%
SUNPHARMA	73 Outperform	₹4.28T	40.93	―	0.89%	9.26%	-5.47%
LUPIN	72 Outperform	₹954.47B	22.06	―	0.57%	15.49%	64.37%
CIPLA	68 Neutral	₹1.21T	22.27	―	0.87%	6.93%	21.55%
TORNTPHARM	66 Neutral	₹1.27T	59.42	―	0.85%	9.11%	18.76%
GLAXO	63 Neutral	₹438.49B	45.90	―	2.09%	4.17%	41.51%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

GlaxoSmithKline Pharmaceuticals Limited Corporate Events

GSK Pharmaceuticals Announces New VP for APAC Finance

GlaxoSmithKline Pharmaceuticals Limited has announced a significant leadership change with Mr. Juby Chandy taking over as Vice President, Finance for the Asia Pacific region effective December 1, 2025. This strategic appointment is expected to enhance the company’s financial leadership across Asia Pacific markets, ensuring continuity as Mr. Chandy will also remain Chief Financial Officer until a successor is appointed.